Semaglutide has transformed the treatment of diabetes and obesity, but researchers are now asking whether its effects could extend beyond blood sugar and body weight.
A large Swedish study has found an unexpected link between semaglutide use and fewer psychiatric hospital admissions among people with bipolar disorder.
The study was led by Professor Mark Taylor of Griffith University and was published in Acta Psychiatrica Scandinavica. Researchers examined nationwide data covering nearly 15,000 people with bipolar disorder who had been prescribed GLP-1 medicines over a 15-year period.
Bipolar disorder causes episodes of major changes in mood. During manic episodes, a person may have unusually high energy, need little sleep, speak rapidly or make risky decisions, while depressive episodes can bring low mood, loss of interest and severe difficulties with everyday life.
Treatment can greatly reduce these problems, but bipolar disorder often requires lifelong care. Relapses can still occur, and severe episodes may lead to emergency treatment or hospitalization.
Physical health is another major concern for people with bipolar disorder. Diabetes and obesity occur frequently in this group, and cardiovascular disease contributes to poorer long-term health outcomes.
Some psychiatric medicines can contribute to weight gain and changes in blood sugar, although medication is only one part of the explanation. Genetics, diet, physical activity, sleep and the biology of bipolar disorder itself may also play roles.
This connection between mental and metabolic health has led researchers to look closely at GLP-1 receptor agonists. These medicines were originally developed to help control type 2 diabetes and are now also widely used to treat obesity.
GLP-1 is a hormone produced naturally after eating. It helps regulate blood sugar and sends signals involved in fullness and appetite, while medicines such as semaglutide imitate these effects for much longer.
The researchers wanted to know whether taking these drugs was associated with changes in serious psychiatric outcomes. Sweden’s nationwide health records allowed them to follow a very large group of people over many years.
The analysis found that semaglutide use was associated with a 21% reduction in the risk of psychiatric hospitalization. In other words, patients were less likely to be admitted for psychiatric care during periods associated with semaglutide use.
This result is notable because hospitalization is usually reserved for more serious mental health episodes. If the association reflects a genuine drug effect, it could mean semaglutide somehow helps reduce the risk of severe relapse.
However, two other GLP-1 medicines in the study, liraglutide and dulaglutide, did not show the same reduction. That finding argues against treating GLP-1 medicines as a single group when considering possible effects on bipolar disorder.
Why semaglutide might be different remains uncertain. Researchers are interested in evidence that GLP-1 pathways may operate in the brain and influence processes beyond appetite.
One theory is that GLP-1 activity could reduce inflammation and stress inside cells. Both processes have been investigated as possible contributors to changes in brain function and mood disorders.
There are also simpler possible explanations. Better diabetes control, weight loss, improved mobility or other physical health improvements could affect mood, sleep, confidence and quality of life, potentially reducing the likelihood of a crisis.
The study cannot separate all these possibilities. It shows a relationship between semaglutide use and hospitalization risk, but it cannot establish exactly why that relationship occurred.
This is a key limitation of observational research. Unlike a randomized clinical trial, patients were not randomly assigned to take semaglutide, so people receiving the medicine may have differed in important ways from themselves during untreated periods or from patients receiving other drugs.
Changes in medical care could also matter. Someone who starts a GLP-1 medicine may have more contact with health professionals, make other lifestyle changes or receive different treatments at the same time.
Another caution is that hospitalization captures only the most severe end of bipolar illness. A study could find fewer admissions without showing whether people experienced fewer mild episodes, better concentration, improved relationships or a better overall quality of life.
Even so, the research has important strengths. Nearly 15,000 people were included, the data came from a nationwide health system, and the long observation period allowed researchers to examine real-world outcomes that would be difficult to study in a small experiment.
The finding also has practical scientific value because it identifies a specific drug worth testing. The lack of a similar result for liraglutide and dulaglutide makes semaglutide an especially interesting candidate for further investigation.
The next major step is a randomized controlled trial. Researchers would need to compare carefully selected patients receiving semaglutide with an appropriate control group while directly measuring mood episodes, hospitalization, physical health, side effects and quality of life.
Such research would also need to determine whether any psychiatric benefit comes directly from effects on the brain or indirectly from improved metabolic health. That distinction could help scientists understand both bipolar disorder and the broader actions of GLP-1 medicines.
Patients should not interpret the study as evidence that Ozempic or Wegovy can replace standard bipolar treatment. Semaglutide is not established as a treatment for bipolar disorder, and decisions about either psychiatric or metabolic medicines should be made with appropriate medical care.
The study is therefore best viewed as a promising signal rather than proof of a new therapy. If clinical trials confirm the association, however, a medicine already widely used for diabetes and obesity could eventually offer an unexpected additional benefit for some people living with bipolar disorder.
Source: Griffith University.
